Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease

ConditionAcute Myeloid Leukemia (AML)

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18+

SponsorYehui Tan

About this trial

A multicenter, open-label, prospective, randomized controlled study to optimize the treatment of patients with acute myeloid leukemia based on early peripheral blood minimal residual disease

Eligibility criteria

Qualifiers

Newly diagnosed AML patients confirmed by bone marrow morphology and immunophenotyping.

Complete MICM (Morphology, Immunophenotyping, Cytogenetics, Molecular genetics) work-up.

Age ≥ 18 years.

Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

Disqualifiers

Acute promyelocytic leukemia (APL).

Mixed phenotype acute leukemia (MPAL).

AML patients with known central nervous system (CNS) involvement.

Presence of extramedullary disease (EMD).

Trial design

Treatments tested in this trial

Venetoclax

Treatment groups

70 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Yehui Tan

Lead sponsor

The First Hospital of Jilin University

Sponsor institution

Source ClinicalTrials.gov